Broadfin Capital, LLC - Q1 2019 holdings

$484 Million is the total value of Broadfin Capital, LLC's 43 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 34.0% .

 Value Shares↓ Weighting
IOVA SellIOVANCE BIOTHERAPEUTICS INC$41,162,000
-21.8%
4,328,303
-27.3%
8.50%
+22.7%
NVRO SellNEVRO CORP$38,920,000
+34.4%
622,615
-16.4%
8.04%
+111.1%
CPRX SellCATALYST PHARMACEUTICALS INC$29,871,000
+148.2%
5,856,998
-6.6%
6.17%
+289.9%
PETX BuyARATANA THERAPEUTICS INC$26,129,000
+4.4%
7,258,135
+77.8%
5.40%
+63.9%
BDSI  BIODELIVERY SCIENCES INTL IN$23,188,000
+43.2%
4,375,0660.0%4.79%
+125.0%
RTRX  RETROPHIN INC$22,995,0000.0%1,016,1140.0%4.75%
+57.0%
GBT BuyGLOBAL BLOOD THERAPEUTICS IN$20,924,000
+111.6%
395,309
+64.1%
4.32%
+232.3%
ZGNX SellZOGENIX INC$20,447,000
+4.6%
371,698
-30.7%
4.22%
+64.3%
ADMS SellADAMAS PHARMACEUTICALS INC$17,561,000
-21.3%
2,469,894
-5.5%
3.63%
+23.5%
MYGN NewMYRIAD GENETICS INCcall$16,600,000500,000
+100.0%
3.43%
SBBP SellSTRONGBRIDGE BIOPHARMA PLC$13,904,000
+10.0%
2,792,049
-1.1%
2.87%
+72.7%
LJPC BuyLA JOLLA PHARMACEUTICAL CO$12,827,000
-30.2%
1,994,911
+2.4%
2.65%
+9.7%
BHVN BuyBIOHAVEN PHARMACTL HLDG CO L$12,708,000
+165.7%
246,900
+91.0%
2.62%
+317.2%
ACRS BuyACLARIS THERAPEUTICS INC$12,165,000
-12.3%
2,030,925
+8.2%
2.51%
+37.7%
REPH SellRECRO PHARMA INC$11,193,000
-23.0%
1,909,995
-6.7%
2.31%
+20.9%
MRTX SellMIRATI THERAPEUTICS INC$10,856,000
+28.0%
148,100
-26.0%
2.24%
+100.9%
QTNT SellQUOTIENT LTD$9,899,000
-4.7%
1,098,656
-35.3%
2.04%
+49.6%
HRTX NewHERON THERAPEUTICS INCcall$9,776,000400,000
+100.0%
2.02%
INCY SellINCYTE CORP$8,601,000
-26.2%
100,000
-45.4%
1.78%
+15.9%
NSTG SellNANOSTRING TECHNOLOGIES INC$8,512,000
-20.3%
355,714
-50.6%
1.76%
+25.1%
XENT SellINTERSECT ENT INC$8,472,000
+4.4%
263,500
-8.5%
1.75%
+63.9%
SRRA SellSIERRA ONCOLOGY INC$8,259,000
+28.2%
4,829,832
-1.0%
1.70%
+101.3%
SSKN BuySTRATA SKIN SCIENCES INC$8,169,000
+44.7%
2,866,323
+32.0%
1.69%
+127.4%
DXCM SellDEXCOM INC$8,039,000
-62.7%
67,500
-62.5%
1.66%
-41.4%
ATRS SellANTARES PHARMA INC$8,011,000
-14.5%
2,643,947
-23.2%
1.65%
+34.3%
MYGN NewMYRIAD GENETICS INC$7,968,000240,000
+100.0%
1.64%
IART SellINTEGRA LIFESCIENCES HLDGS C$7,888,000
-11.0%
141,572
-28.0%
1.63%
+39.7%
VRAY  VIEWRAY INC$6,403,000
+21.7%
866,5000.0%1.32%
+91.0%
OPTN SellOPTINOSE INC$6,032,000
+36.9%
585,600
-17.6%
1.24%
+115.0%
SLGL  SOL GEL TECHNOLOGIES$5,739,000
+12.5%
847,7000.0%1.18%
+76.6%
ADMA SellADMA BIOLOGICS INC$5,606,000
-44.5%
1,479,243
-65.0%
1.16%
-12.8%
HRTX BuyHERON THERAPEUTICS INC$5,083,000
+64.3%
207,998
+74.4%
1.05%
+158.0%
VCEL BuyVERICEL CORP$4,772,000
+44.3%
272,550
+43.4%
0.98%
+126.4%
LIVN SellLIVANOVA PLC$4,668,000
+0.1%
48,000
-5.9%
0.96%
+57.3%
AVDL  AVADEL PHARMACEUTICALS PLCsponsored adr$4,468,000
-44.2%
3,102,6730.0%0.92%
-12.3%
NEOS SellNEOS THERAPEUTICS INC$4,207,000
-2.6%
1,611,999
-38.4%
0.87%
+53.0%
MTNB NewMATINAS BIOPHARMA HLDGS INC$2,973,0002,727,272
+100.0%
0.61%
EIGR BuyEIGER BIOPHARMACEUTICALS INC$2,702,000
+85.6%
193,300
+34.9%
0.56%
+192.1%
TLGT SellTELIGENT INC NEW$2,310,000
-40.3%
1,990,983
-29.5%
0.48%
-6.3%
ATEC SellALPHATEC HOLDINGS INC$1,174,000
+14.0%
442,966
-1.5%
0.24%
+79.3%
OPNT NewOPIANT PHARMACEUTICALS INC$1,122,00085,484
+100.0%
0.23%
OSMT SellOSMOTICA PHARMACEUTICALS PLC$1,108,000
-72.9%
307,854
-41.8%
0.23%
-57.5%
NVLNF SellNOVELION THERAPEUTICS INC$897,000
-13.2%
729,301
-40.7%
0.18%
+36.0%
IDRA ExitIDERA PHARMACEUTICALS INC$0-486,604
-100.0%
-0.18%
KALA ExitKALA PHARMACEUTICALS INC$0-339,119
-100.0%
-0.22%
DOVA ExitDOVA PHARMACEUTICALS INC$0-351,800
-100.0%
-0.35%
KALV ExitKALVISTA PHARMACEUTICALS INC$0-143,129
-100.0%
-0.37%
TNDM ExitTANDEM DIABETES CARE INC$0-89,100
-100.0%
-0.44%
ALXN ExitALEXION PHARMACEUTICALS INC$0-58,700
-100.0%
-0.75%
NVRO ExitNEVRO CORPcall$0-300,000
-100.0%
-1.53%
GBT ExitGLOBAL BLOOD THERAPEUTICS INcall$0-350,000
-100.0%
-1.89%
TSRO ExitTESARO INCcall$0-325,000
-100.0%
-3.17%
TSRO ExitTESARO INC$0-442,219
-100.0%
-4.32%
XBI ExitSPDR SERIES TRUSTput$0-700,000
-100.0%
-6.60%
SPY ExitSPDR S&P 500 ETF TRput$0-700,000
-100.0%
-23.00%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Broadfin Healthcare Master Fund Ltd #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
BIODELIVERY SCIENCES INTL IN27Q4 20194.8%
HERON THERAPEUTICS INC24Q4 20199.0%
LA JOLLA PHARMACEUTICAL CO24Q4 20197.7%
RECRO PHARMA INC24Q4 20194.1%
ANTARES PHARMA INC24Q3 20193.4%
RETROPHIN INC23Q3 20197.0%
ARATANA THERAPEUTICS INC22Q2 20198.1%
MIRATI THERAPEUTICS INC22Q1 20197.9%
CATALYST PHARM PARTNERS INC22Q3 20196.2%
ANGIODYNAMICS INC21Q3 20186.6%

View Broadfin Capital, LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Broadfin Capital, LLC Q1 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Eiger BioPharmaceuticals, Inc.Sold outJanuary 04, 202100.0%
LA JOLLA PHARMACEUTICAL COSold outJanuary 04, 202100.0%
STRATA Skin Sciences, Inc.June 23, 20201,529,3924.5%
Teligent, Inc.Sold outFebruary 25, 202000.0%
Neos Therapeutics, Inc.Sold outFebruary 14, 202000.0%
Aclaris Therapeutics, Inc.February 13, 20201,888,0394.6%
Adamas Pharmaceuticals IncSold outFebruary 13, 202000.0%
ADMA BIOLOGICS, INC.Sold outFebruary 13, 202000.0%
AVADEL PHARMACEUTICALS PLCFebruary 13, 20201,029,0122.8%
CATALYST PHARMACEUTICALS, INC.Sold outFebruary 13, 202000.0%

View Broadfin Capital, LLC's complete significant-ownership history.

Latest filings
TypeFiled
42022-03-22
42022-02-15
42022-01-31
42021-11-22
42021-11-15
42021-11-09
42021-08-10
42021-05-13
SC 13G/A2021-01-04
SC 13G/A2021-01-04

View Broadfin Capital, LLC's complete filings history.

Compare quarters

Export Broadfin Capital, LLC's holdings